Comments
Drug major Cipla on Wednesday announced its partnership with the Premier Medical Corporation Pvt Ltd for commercialisation of the rapid antigen test kits for Covid-19 in India.
“In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Pvt Ltd,” Cipla said in a regulatory filing.
The company said it will commence supply of rapid point-of-care nasopharyngeal swab tests from this week.
The test will be marketed under the brand name ‘CIPtest’
Shares of Cipla were trading 0.29 per cent higher at ₹783.95 apiece on the BSE in morning trade.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.